Literature DB >> 21058412

Analytical procedures for the determination of the selective serotonin reuptake inhibitor antidepressant citalopram and its metabolites.

Nora Unceta1, M Aranzazu Goicolea, Ramón J Barrio.   

Abstract

The antidepressant citalopram (CIT) is a potent and highly selective serotonin reuptake inhibitor (SSRI) which has been introduced in therapy as a racemic drug. CIT has been used to treat central nervous system affective disorders such as depression, anxiety, obsessive-compulsive disorders, various phobias, borderline personality disorders, bipolar disorders as well as indications wherein inhibition of serotonin reuptake is desired. CIT is demethylated to demethylcitalopram (DCIT) and didemethylcitalopram (DDCIT), which retain considerable activity as SSRIs. Therefore, in recent years, the monitoring of the levels of these analytes in biological fluids for toxicological and therapeutic purposes has been a target worthy of interest. In addition, the differences in activity between CIT enantiomers established the need to assess its behaviour in the field of pharmacological research. It is also necessary to develop analytical methodologies that make it possible to determine the levels of enantiomer concentrations. This review includes most of the published analytical methods for achiral assay of racemic CIT and its metabolites based on high-performance liquid chromatography coupled with UV, fluorescence and mass spectrometry detectors, capillary electrophoresis and gas chromatography with mass spectrometry detectors among others. With regard to the monitoring of enantiomers of CIT and of its metabolites, stereoselective methods based on chiral chromatographic columns, chiral additives in mobile phases and on the derivatization with a chiral reagent are also collected. In addition, different procedures of extraction are mentioned as well as liquid-liquid extraction, solid-phase extraction, solid-phase microextraction, automated online extraction or liquid-phase microextraction in different biological and environmental samples. 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21058412     DOI: 10.1002/bmc.1542

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  4 in total

1.  P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents.

Authors:  Fionn E O'Brien; Richard M O'Connor; Gerard Clarke; Timothy G Dinan; Brendan T Griffin; John F Cryan
Journal:  Neuropsychopharmacology       Date:  2013-05-14       Impact factor: 7.853

Review 2.  Abuse and misuse of antidepressants.

Authors:  Elizabeth A Evans; Maria A Sullivan
Journal:  Subst Abuse Rehabil       Date:  2014-08-14

3.  The Effect of Escitalopram on Central Serotonergic and Dopaminergic Systems in Patients with Cervical Dystonia, and Its Relationship with Clinical Treatment Effects: A Double-Blind Placebo-Controlled Trial.

Authors:  Evelien Zoons; Marina A J Tijssen; Yasmine E M Dreissen; Marenka Smit; Jan Booij
Journal:  Biomolecules       Date:  2020-06-08

4.  Enantioseparation of Citalopram by RP-HPLC, Using Sulfobutyl Ether-β-Cyclodextrin as a Chiral Mobile Phase Additive.

Authors:  Yangfeng Peng; Quan Sophia He; Jiang Cai
Journal:  Int J Anal Chem       Date:  2016-01-05       Impact factor: 1.885

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.